BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Biogen (BIIB) shares have experienced a five-day rally, increasing 14% and adding $3.3 billion to its market capitalization, primarily driven by the regulatory approval of its Alzheimer's drug, Leqembi, in China. Although Eisai books sales, Biogen recognizes 50% of Leqembi's profits and losses, with the drug contributing $160 million in revenue last quarter, a figure expected to grow significantly following the Chinese market entry. This surge indicates increasing investor confidence, though such momentum can precede market reversals.

Analysis

Biogen (BIIB) has experienced a significant short-term rally, with its stock appreciating 14% over five consecutive days, adding approximately $3.3 billion to its market capitalization. This surge is directly attributed to the pivotal regulatory approval of its Alzheimer's treatment, Leqembi, in China. Although Biogen's partner Eisai books all sales, Biogen's 50% share of profits and losses from the drug is material; it recognized $160 million in revenue from Leqembi in the most recent quarter, a figure now expected to grow substantially with access to the Chinese market. Despite this positive momentum, the stock's year-to-date performance of +1.5% significantly lags the S&P 500's +14.2% return, indicating that the recent gains are recovering from a period of underperformance. The strong positive ticker sentiment (0.7) reflects optimism around this specific catalyst, but the overall cautious tone of the article suggests that while investor confidence is increasing, the rapid gains could be susceptible to a reversal.

Key Decisions for Investors

• Investors should view the Leqembi approval in China as a significant fundamental catalyst that could materially alter Biogen's earnings trajectory, warranting a re-evaluation of the company's long-term growth profile.
• Given the stock's rapid 14% run-up in a short period against a backdrop of significant year-to-date underperformance, it may be prudent to anticipate potential short-term volatility and profit-taking.
• Monitor upcoming quarterly earnings for concrete data on the Leqembi launch in China, as the actual sales ramp-up will be the primary validation for sustaining the current valuation and closing the performance gap with the broader market.